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821-3 Amlodlplne Decreases Myocardial Oxygen 
Consumption via Angiotenain 4 Receptor: A Unique 
Effect of the R+ Enantiomer 
Seema Mital, Edward Shesely, Thomas H, Hintze, Columbia University, New York, New 
York, New York Medical College, Valhalla, New York. 
Background: Amlodipine decreases myocardial oxygen consumption (MVO2) via R+ 
enantiomer mediated endothelial nitric oxide (NO) release. We investigated the role of 
angiotensin (AT) 2 and 4 receptors in mediating this effect. 
Methods: We measured MVO2 in vitro using the Clark type oxygen electrode in isolated 
LV myocardial segments obtained from (i) wild-type and AT2 receptor knock-out (KD) 
mice (n=5), and (ii) explanted failing human hearts obtained at the time of heart trans- 
plantation (n=2). We studied the effect of increasing doses of R+ enantiomer (10-7M -10- 
5 M) on MVO2 with and without (i) NO synthase inhibitor, nitro-L-arginine methyl ester (L- 
NAME, 10-3 M), (ii) AT2 receptor blocker, PD 123319, 10-6-10-5M, and (iii) specific AT4 
receptor blocker, divalyl angiotensin 4,10-5M. 
Results: Wild-type mice: R+ caused a dose-dependent decrease in MVO2 (-24±8% at 
highest dose, p<O,05). This effect was inhibited by L-NAME (-17±7%) and 10-5M PD 
123319 (2±7%). AT2 KO mice: R+ caused a dose-dependent decrease in MVO2 (- 
25±3% at highest dose, p<0.05) and this was not blocked by 10-6M PD123319, selective 
AT2 receptor antagonist suggesting an alternate receptor/pathway. At higher concentra- 
tion of 10-5M, PD123319 blocked the effect of R+ (-5±2%, p<0.01). At this dose, PD 
compound appears to be a nonselective AT receptor antagonist possibly acting on AT4 
receptor, L-NAME caused a 33% reduction in the effect of R+. Human myocardium: R+ 
decreased MVO2 with a -20±1% decrease at highest dose. This effect was attenuated by 
both L-NAME and 10-5M PD123319. Also, specific AT4 receptor blocker caused a 50% 
attenuation of R+ effect. Conclusion: The R+ enantiomer of amlodipine decreases MVO2 
by AT4 receptor mediated NO release in AT2 receptor knock-out mice. In failing human 
myocardium, this effect also appears to be mediated by AT4 receptors. 
11:45 a.m. 
821-4 Angiotensin II Receptor Antagonism and ACE Inhibition 
Ameliorate Hyperinsulinemia and Obesity in a Murine 
Model of Polygenic Obesity 
Jan R. Ortleoc. Jutta Breuer, Karin Kluge, Reinhard Kluge, Hans-Georg Joost, Medical 
Clinic I RWTH University Hospital, Aachen, Germany, Institute for Pharmacology and 
Toxicology, Aachen, Germany 
Background: ACE inhibitors are well established in the prevention of hypertension- 
associated complications of the metabolic syndrome. This study was performed in order 
to assess the effects of the ACE inhibitor captopril and of the angiotensin II receptor 
antagonist irbesartan on other conditions of the metabolic syndrome in an animal model. 
Methods: Male NZO/BL6 F1 mice were treated with captopril, irbesartan, or placebo for 
ten months. Treatment with captopril and irbesartan in equivalent dosage was controlled 
by monitoring the blood pressure (BP). At the end of the study, gain of body weight (BW), 
serum levels of insulin, cholesterol, triglycerides and creatinine, cardiac weight and 
degree of atherosclerosis were determined. 
Results: Control animals treated with placebo developed a metabolic syndrome with 
obesity (55.5 + 6.3 g), hypertension (t46 + 10 mmHg), hyperinsulinemia (7.2 + 5.7 ng/ 
ml), hypercholesterolemia (5.1 + 0.7 mmoVI), cardiac hypertrophy (269 + 44 mg) and ath- 
erosclerotic plaques in the ascending aorta (3.6 + 1.5 p.rr~). Treatment with ACE inhibitor 
or angiotensin II receptor antagonist significantly (p<0.001) reduces hypertension (73 + 5 
and 78 + 11 mmHg), cardiac hypertrophy (203 + 26 and 202 + 18 mg) and atherosclero- 
sis (2.2 _+ 0.9 and 1.8 _+ 0.8 Hm2). In addition captopril and irbesartan prevented the devel- 
opment of obesity (42.2 + 3.5 and 38.3 ± 2.8 g) and hyperinsulinemia (3.6 ± 1.5 and 1.8 
± 0.4 ng/ml), Irbesartan being somewhat more effective than captopril in the prevention 
of hyperinsulinemia (p<0.01). 
Conclualon: In a mouse model of the obesity associated metabolic syndrome, long term 
treatment with an ACE inhibitor or an angiotensin II receptor antagonist, can ameliorate 
obesity and hypednsufinemia. 
Noon 
821-5 Chronic Angiotensin II (AT1) Receptor Antagonism 
Selectively Enhances Renal cGMP Production With 
Improved Renal Function in Experimental Overt 
Congestive Heart Failure 
Homo H. Chert, John B. Osborn, Gall J. Harry, John C. Burnett, Jr., Mayo Clinicand 
Foundation, Rochester, Minnesota. 
BACKGROUND: Recent studies have reported that preservation of renal function is an 
important predictor of survival in congestive heart failure (CHF). A hallmark of overt CHF 
is an attenuated renal cGMP production to endogenous natriuretic peptides (NPs) and 
nitdc oxide (NO), which may lead to decline in renal function. Studies have also shown 
that Angiotensin II (ANG II) activates cGMP phosphodiesterase resulting in increased 
cGMP degradation. We therefore hypothesized that chronic AT1 receptor antagonism 
would restore the renal cGMP production in response to endogenous NPs and NO as 
assessed by urinary cGMP with improved sodium excretion. 
METHODS: We determined the cardiorenal actions of chronic AT1 blockade (Valsartan, 
Novartis, 320 mg daily for 10 days, n=5) in a canine model rapid ventricular pacing 
induced overt CHF (245 bpm for 10 days) as compared to a non-treated group (n=5). 
RESULTS: After 10 days of chronic AT1 receptor antagonism, urinary sodium excretion 
increased (12.4 ± 3.3 vs 2.7 ± 1.3 uEq/min,p<0.05) in association with a marked increase 
in urinary cGMP excretion (1558 ± 200 vs 139 ±65 pmol/min, p<0.05) as compared to the 
non-treated group. The natriuretic response to chronic AT1 receptor antagonism was 
localized to the inner medullary collecting duct by the lithium clearance technique, a 
nephron site rich in NPs receptors and sensitive to NO, as distal tubular fractional sodium 
reabsorption decreased in the AT1 blocker group vs non-treated group (97.6 ± 0.3 vs 
98.9 ± 0.5 %, p<O.05). These renal responses where selective as they occurred in the 
absence of any changes in plasma NPs or cGMP. Chronic AT1 receptor antagonism also 
reduced cardiac filling pressures consistent with cardiac unloading. 
CONCLUSION: We conclude that chronic AT1 receptor antagonism in experimental 
overt CHF enhances renal cGMP production, the common secondary messenger for the 
NPs and NO system resulting in improved renal tubular function and sodium excretion. 
This study provides insight into renal and humoral pathophysiological actions of ANG II 
and the AT1 receptor in CHF and mechanisms by which AT1 receptor antagonism may 
mediate beneficial therapeutic properties by targeting the kidney in this disease state. 
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1108-71 Optical Imaging of Adenoviral Mediated Cardiac Gene 
Expression in Living Rats 
Joseoh C. Wu, Masa Inubushi, Heinrich Schelbert, Sanjiv S. Gambhir, UCLA Schoolof 
Medicine, Los Angeles, California, 
Background: Direct injection of edenovirus into the heart is useful for studying reporter 
gene constructs. However, most studies rely on postmortem analysis. We have validated 
a novel method of studying rat cardiac gene expression of CMV driven firefly luciferase 
(Ad-CMV-FL) utilizing a cooled Charged Couple Detector (CCD) camera. 
Methods: Rats underwent a standard thoracotomy. In one group, lx10 s pfu was injected 
into left ventdcular wall (n=3). Another group received serially diluted titers (lx109 to 
lx l  06 pfu). Control rats were injected with 1 x109 pfu of Ad-CMV-HSV1-sr39tk expressing 
mutant hymidine kinase (n=3). Images were acquired on days 2 and 5 after i.p. injection 
of luciferin (125 mg/kg) and data expressed as relative light unit per minute (RLU/min). 
Results: Rats imaged serially show cardiac FL activity of 172,423 ± 8,066 (clay 2) and 
252,755 ± 83,739 RLU/min (day 5). Rats injected with diluted titers show considerable FL 
activity at day 5:1,452 RLU/min (Ix107 pfu) and 248 RLU/min (lx10 s pfu). All values are 
statistically significant (p<0.05) compared to control rats showing background signals 
(10±5 RLU/min). 
Conclusion: In summary, this study demonstrates the feasibility of imaging the location, 
magnitude, and persistence of cardiac reporter gene expression in rats over time. The 
cooled CCD camera produces consistent results and the detection sensitivity is very 
high, down to lx10 s pfu. This is the first demonstration of imaging cardiac gene expres- 
sion in a living subject. 
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1105-72 DNA Chip Analysis of Akt-Regulated Genes in 
Endothelial Cells Reveals Activation of Many 
Proangiogenic Pathways 
Hvo-Soo Kim. Yuri Ivashchenko, Kenneth Walsh, Boston University Medical Center, 
Boston, Massachusetts, Seoul National University Hospital, Seoul, South Korea. 
Background: The serine-threonine protein kinase Aktl is activated downstream of 
numerous angiogenic factors in endothelial cells. To understand the role of this signaling 
pathway in the angiogenic response, we used adenovirus-mediated Aktl gene transfer 
and high-throughput affymatrix oligonucleotide microarrays to examine the Akt-regulated 
genes in human umbilical vein endothelial cells (HUVEC). 
Methods: HUVEC were either mock-infected or infected with adenoviral vectors 
expressing constitutively-active Aktl or ~-galactosidase (moi=100). Under these condi- 
tions, transfection efficiency was 95% or greater. At 24 hours post-treatment, RNAs were 
isolated, labelled during reverse-transcription, and hybridized to oligonucleotide microar- 
rays, the Human Genome U95A array. The genes that showed a significant change of 
expression (>2-fold increase or decrease) in both replicate and duplicate assays were 
selected and confirmed by quantitative PCR. 
Results: Constitutive activation of Akt signaling altered the expression of 130 genes of a 
total of 12,000 genes analyzed. Consistent with the pro-angiogenic role attributed to Akt, 
there were many angiogenesis-related growth factors and cytokines that were induced 
by an increase in Akt signaling. These include VEGF-A, VEGF-C, IL-8, GRO(Growth 
Regulated Oncogene)-c~, GRO-13, GRO-y, Cox2, HOX, and heme oxygenase-1. Akt sig- 
naling also induced the expression of adhesion molecules (VCAM-1, ICAM-1, ELAM-1) 
associated with endothelial cell activation. As expected from the documented pro-sur- 
vival action of Akt, several anti-apoptotic genes (HSP70) were increased. Akt also 
increased a series of genes involved in the cholesterol synthesis. Finally, Akt exagger- 
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ated the immune response against viral infection by enhancing the expression of many 
interferon-inducible genes that were activated by adenovirus carry!ng ~-gal gene com- 
pared to the mock treatment. 
Conclusion: These data show that Akt controls a genetic program that promotes the 
activation and survival of endothelial cells. Furthermore, these data provide a framework 
to understand how Akt signaling controls the blood vessel growth at a molecular level. 
1105-73 DNA Microarray Analysis of the Progressive 
Arterialization and Intimal Hyperplasia of Venous Grafts 
in a Canine Model 
Matthew D. Bacchetta. Ying Zhou, Ronda Chert, Sanjay A. Samy, Arash Salemi, Adam 
Hamawy, Lufei Hu, Karl H. Krieger, O. Wayne Isom, Wilson Ko, Daniel F. Catanzaro, 
New York Presbyterian Hospita/-Wei/I Medical College of Come//Universi~ New York, 
New York. 
Intimal hyperplasia of arterialized venous grafts is a leading cause of coronary artery 
bypass graft (CABG) failure. DNA array analysis of tissue RNA provides a means to 
identify genes involved in this process. DNA arrays are unavailable for the dog, which is 
used as a model for CABG surgery. This study evaluated the use of a heterologous DNA 
array (rat) to measure RNA in vein grafts from dogs. Mongrel dogs underwent bilateral 
carotid venous interposition grafts and left internal mammary artery (LIMA) graft to a cor- 
onary artery. Samples of the grafts were collected for histologic and RNA analyses at 3-, 
10-, and 30-days (n=4 per time point). RNA levels were measured using heterologous 
cDNA microarrays(Affymetrix~ rat U34). Each animal served as its own control using a 
vein sample saved at the initial surgery. Gene expression was analyzed using dChip soft- 
ware, Among the 8,784 genes represented in the probe set, 8,8-10% were assessed as 
present in the venous mRNA samples. Although lower than the percentage present when 
RNA was analyzed with GeneChips~ of the corresponding species (25-40% for rat vas- 
cular tissue in our lab), the levels were highly consistent across samples. Significant' 
changes were found in mRNA levels in arterialized venous grafts for 63 genes (>2-fold, 
p<0.05). Hierarchical clustering revealed four patterns of gene expression: (1) early stim- 
ulation (3 days) followed by suppression (10 & 30 days) (4 genes), (2) early and sus- 
tained stimulation (27 genes), (3) early and sustained suppression (36 genes), and (4) 
mid point stimulation (10 days) flanked by early and late suppression (6 genes). The fold 
change in mRNA levels ranged from -25 to +20-fold. In addition to known structural (e. g. 
actin, collagen, fibronectin) and regulatory proteins(fos), a number of novel ESTs were 
also identified. Histological findings (e. g. collagen deposition and smooth muscle hyper- 
plasia) were consistent with changes observed in gene expression, This study demon- 
strates the feasibility of using heterologous (rat) gene chips to analyze the progression of 
intimal hyperplasia in artedalizing canine vein grafts. It also identified possible molecular 
targets for gene therapy or pharmaceuticals to improve graft life. 
1105-74 Prof i l ing Gene Expression in Atherosclerosis Using 
DNA Microarrays 
Kavitha M Chinnaivan, Arun Sreekumar, Waiter M. Whitehouse, Jr., Naresh T. 
Gunaratnam, Stuart A. Winston, Arul M. Chinnaiyan, Saint Joseph Mercy Hospital, Ann 
Arbor, Michigan, University of Michigan, Ann Arbor, Michigan. 
Background. Atherosclerosis (AS) and its sequelae account for high morbidity and mor- 
tality in the U.S. Defining the genes responsible for growth, stability or rupture of the ath- 
erosclerotic plaque can aid in understanding its pathogenesis and designing therapies. 
While traditional approaches focus on one gene at a time, cDNA microarray technology 
provides a "global" perspective. 
Methods. Plaque specimens were collected from routine carotid endarterectomies. Tiny 
portions of normal adjacent endothelium taken from each patient provided comparison. 
Control was non-atherosclerotic artery obtained at autopsy, Total RNA extracted from 
samples was used to generate fluorascently labeled cDNA probes using reverse tran- 
scdptase. The probes were hybridized to a high-density, 10K human oDNA microarray ( 
DNA "chip") comprised of > 4,500 known human genes + > 5000 expressed sequence 
tags (ESTs). Gene expression data deposited into a relational database was analyzed. 
Hierarchical clustering of data and visualization using the Traeview program defined 
coordinated patterns of gene expression. Genes differentially expressed were validated 
by RT-PCR. 
Results, >130 genes differentially expressed in plaques relative to normal arterial tissue 
were identified. Complete concordance was obtained between microarray data and RT- 
PCR for 18 genes tested. Many genes were previously implicated in AS (e.g., VCAM-1) 
forming independent validation for our study. Importantly, genes not previously implicated 
in AS were identified, including OB-Cadherin-ll, Cadherin 13, Herin, Cathepsin O, Kal- 
1, RBM3 TNR3, LIM7, IGF*2, IGFBP5 and OSF-2. The cluster of 130 genes was classi- 
fied into distinct functional groups, including call adhesion and extracellular matrix com- 
ponents, transcription factors, enzymes, complement and MHC, growth factors, kinase 
and phosphatase, free radical scavengers, glycoproteins and proteoglycans, and miscel- 
laneous. 
Conclusion. In this study, we delineated a cohort of novel genes significantly dysragu- 
lated in the human atherosclerotic plaque. Future studies are needed to define the func- 
tional role of these genes in the pathogenesis of AS and their potential as therapeutic 
targets. 
1105-75 Impairment of Neovascularization by Smoking: Role of 
HIF-lalpha and VEGF 
Soohie Elise Michaud, Catherine Menard, Louis-Georges Guy, Giuseppa Gennaro, Alain 
Rivard, University of Montreal, Notre-Dame Hospital Montreal Quebec, Canada. 
Background: Smoking is a major nsk factor for coronary and peripheral artery diseases. 
However, the impact of smoking on collateral vessel development has not been studied. 
Accordingly, we studied the effect of smoking on angiogenesis in the setting of vascular 
ischemia. Methods and Results: Hindlimb ischemia was created by femoral artery resec- 
tion in mice exposed to cigarefte smoke (MES, n=20) and control mice (n=2O). We found 
that smoking was associated with a significant reduction in blood flow recovery as 
assessed by laser Doppler flow ratio (LDFR) between the ischemic and the normal limb. At 
day 21 after surgery, MES had a LDFR of 0.60+0.11 vs 0.78_+0.07 for controls (p<0,001), 
and this impaired blood flow perfusion in MES was still present at day 28 after surgery 
(LDFR: 0.63_+0.03 vs 0.80_+0.03, p<0.001). CD31 immunostaining confirmed the laser Dop- 
pler data by showing a significant reduction in capillary density in the MES at day 28 after 
surgery (477_+34 capillaires/mm 2 vs 681+54 capillades/mm 2 in controls p<O.05). Western 
blot analysis of ischemic muscles demonstrated that smoking was associated with a signif- 
icant reduction in vascular endothelial growth factor (VEGF) expression at days 3, 7 and 14 
after surgery. Moreover, this reduced VEGF expression correlated with a significant reduc- 
tion in the expression (Western blot) and binding activity (electromobility shift assay) of the 
transcription factor HIF-lc~ in MES. Lower HIF-lc( binding activity and VEGF expression 
were also observed in vascular smooth muscle cells that were exposed to cigarette smoke 
extract in vitro. Importantly, rescue of HIF-le expression using an adenoviral gene delivery 
strategy resulted in a significant improvement of blood flow recovery in MES. Conclusion: 
1 ) Angiogenesis in ischemic vascular disease is impaired by smoking 2) This impairment in 
neovessel formation is due, at least in part, to the negative effect of smoking on HIF-lc( and 
VEGF expression under hypoxic conditions 3) Smoke-induced impairment of angiogenesis 
can be rescued by adeno-HIF gene therapy. 
1105-76 The Matrix Protein Bone Sialoprotein Enhances 
Calcification in Vascular Smooth Muscle Cells 
Lorraine A. Fitzoatrick. Sean Harrington, Tim O'Brien, Mayo Clinic, Rochester, 
Minnesota. 
Background: Matrix proteins are an integral component of the atherosclerotic plaque 
and regulate calcification. The role of these proteins in the calcification process is poorly 
understood. Vascular smooth muscle cells (VSMCs) are an integral part of the plaque 
and produce matrix proteins including osteopontin, osteocalcin, bone sialoprotein and 
type I collagen. The calcification within an atherosclemtic plaque is an active and regu- 
lated process with similarities to Ossification in bone. We explored the role of two matrix 
proteins that are associated with bone calcification, osteopontin (OPN) and bone sialo- 
protein (BSP). Methods: VSMCs were isolated from the coronary arteries of sexually 
mature pigs. For antisense experiments, oligonucleotides directed at OPN or BSP were 
made, utilizing the coding strand as a control. A replication defective adenovirus (AD) 
human serotype 5 was constructed with either OPN (AD-OPN), BSP (AD-BSP), or null 
(AD-NuII) inserts driven by a CMV promoter. VSMCs were infected and maintained in 
DMEM. VSMCs were fixed and stained for calcium using the Von Kossa method and 
nodules and calcium were quantified. Results: In nontransfected VSMCs, inhibition of 
BSP expression by oligonucleotides resulted in a decrease in calcified nodules while 
inhibition of OPN expression caused an increase in calcification. Electron micrographs 
confirmed the presence of calcium crystals, similar to those found in bone-forming ostao- 
blasts. To further evaluate the role of OPN and BSP, ceils were transfected with AD-BSP, 
AD-OPN or AD-NulI. There was a marked and significant increase in nodule calcification 
in VSMCs containing AD-BSP compared to AD-Null (P<0.02) or AD-OPN (P<0.00001). 
In contract, AD-OPN VSMCs revealed marked inhibition of calcified nodules compared to 
AD-BSP. Conclusion; VSMCs and matrix proteins are integral components of the ath- 
erosclerotic plaque. These findings suggest that bone sialoprotein and ostaopontin con- 
tribute to regulation and play an unique role in the calcification process during plaque 
development. 
1105-77 Evaluation of the Dynamics of Substance Delivery via 
Retrograde Perfusion of the Coronary ~°inus in Dogs 
With Acute and Chronic Cardiac Ischemia 
Eduard Fiehn. Wilfried Roethy, Anguo Gu, Kotaro Suehiro, Geng-Hua Yi, Jie Wang, 
Daniel Burkhoff, Columbia University - Division of Circulatory Physiology, Department of 
Medicine, New York Ci~ New York. 
Background: Coronary sinus (CS) ratroperfusion (R) is a potential way to deliver sub- 
stances to the myocardium, particularly in the setting of ischemia where arterial delivery 
may be limited. We determined optimal conditions to achieve preferential substance 
delivery to ischemio myocardium with minimal systemic appearance. 
Methods: Anesthetized dogs were instrumented for CS-R, Isohemia was induced 
acutely by LAD ligation (n=14) or chronically by ameroid constrictor (n=3) implanted 3 
weeks earlier. The CS was occluded and R performed for 10 min. Colored microspheres 
(MS) were injected into the CS and their ~ppearance in different regions of the heart and 
in the kidneys (to index systemic delivery) were quantified. The following parameters 
were varied: catheter position proximal in CS (n=6) vs distal in the great cardiac vein 
(n=8); perfusion with blood (n=6) vs crystalloids (n=8); low (5-20 ml/min) vs high (50-250 
ml/min) R flow. 
Results: During acute isohemia, more MS appeared in ischemic LAD tissue (arterial flow 
0.3±0.2 ml/min/g; 4297±2457 MS/g tissue) compared to non-ischemic LCx tissue (arte- 
rial flow 1.4±0.3 ml/min/g; 1058±456 MS/g tissue, p<.05). Distal catheter placement in 
combination with low-flow CS-R reduced the amount of MS shunted to the systemic cir- 
culation by 85% compared to proximal placement and high flow perfusion. With chronic 
LAD occlusion, resting flow was normal in LAD area (1.1±0.3 vs 0.9±0.2 ml/min/g in the 
LCx area) and CS-R did not provide preferential MS delivery (1133±691 vs 1946±1450 
MS/g in the LAD and LCx territories, respectively). 
Conclusion: CS-R leads to preferential substance delivery to acutely ischemic areas, 
but not in the setting of chronic LAD occlusion where resting antegrade blood flow is nor- 
mal. Systemic appearance of injected substances can be minimized using an optimized 
ratroperfusion protocol. These results will help guide understanding of whether it is 
advantageous to consider CS-R as a means of delivering a particular substance (e.g., 
drug, gene, growth factor, etc.) in a particular setting (normal, acute or chronic ischemia). 
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